---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-039826"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T17:11:10.228570+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics doses first patient in [212Pb]VMT01 plus nivolumab combo cohort

## Summary
- First patient dosed with [212Pb]VMT01 at 1.5 mCi in combination with nivolumab (Opdivo) for MC1R+ metastatic melanoma Phase 1/2a trial.
- Earlier monotherapy cohorts showed no dose-limiting toxicities and early signs of anti-tumor activity, presented at SMR October 2024.
- FDA granted Fast Track Designation for [212Pb]VMT01 in unresectable or metastatic melanoma with MC1R expression in September 2024.
- New cohort explores dual mechanism of targeted alpha-particle therapy plus PD-1 blockade to improve patient outcomes.

## SEC filing metadata
- accession: 0000950170-25-039826
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025039826/0000950170-25-039826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025039826/catx-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-039826
- JSON: https://secwatch.observer/filing/0000950170-25-039826.json
- Plain text: https://secwatch.observer/filing/0000950170-25-039826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.